Indoor Air Filtration and Young Adults Health Study
Cardiopulmonary Health Effects of Indoor Air Purification and Other Indoor Environmental Conditions Among Young Healthy Adults in Beijing, China
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100191
- Peking University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Living in Beijing for more than one consecutive years;
- College students between 18-28 years;
Exclusion Criteria:
- Current or past smokers;
- Body mass index (BMI) over 28.0 kg/m2.
- Alcohol addict;
- Having thoracic surgery history;
- History of diagnosed chronic disease;
- Hepatitis B / hepatitis C virus patient / carrier;
- Unwilling or unable to provide informed consent or cooperate with all research related procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Real purification
Air purifier turned on.
|
Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
|
|
Sham Comparator: Sham purification
Air purifier turned off.
|
Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in heart rate variability
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including the standard deviation of all normal-to-normal R-R intervals (SDNN) in millisecond, standard deviation of sequential five-minute R-R interval means (SDANN) in millisecond, root-mean-square difference of successive normal R-R intervals (rMSSD) in millisecond, low frequency (LF) in squared millisecond, and high frequency (HF) in squared millisecond.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in blood pressure
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including the systolic blood pressure (SBP) in mmHg, diastolic blood pressure (DBP) in mmHg, and pulse pressure (PP) in mmHg.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in pulmonary function
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including forced expiratory volume in 1 s (FEV1) in liter, forced vital capacity (FVC) in liter, forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) ratio, and peak expiratory flow (PEF) in liter per second.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in levels of airway inflammation
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Respiratory inflammation Fractional exhaled nitric oxide (FeNO) test would be conducted.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of C-reactive protein (CRP)
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Examining the C-reactive protein (CRP) in blood sample to characterize the levels of inflammation.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of 8-hydroxydeoxyguanosine (8-OHdG)
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Examining the 8-hydroxydeoxyguanosine (8-OHdG) in urine sample to characterize the levels of oxidative stress.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of sleep-related parameters
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including time in bed in minute, total sleep time and sleep stage time in minute.
The time in bed and total sleep time would be calculated to sleep efficiency in percentage.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of sleep-breathing parameters
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including blood oxygen saturation in percentage and heart rate in bpm.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of cognitive function
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including short-term memory and delayed memory in unit measured by the standard Stroop Test, as well as executive function in unit measured by the Harmonized Cognitive Assessment Protocol.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of cognitive function-related biomarkers
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including serum brain derived nerve factor (BDNF) in ng/mL, S100B protein in ng/mL, and neuron-specific-enolase (NSE) in ng/mL.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of blood cell parameters
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including white blood cells in unit, red blood cells in unit, and platelets in unit measured by blood routine examination.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of systematic inflammation and oxidative stress indicators
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including interleukin-6 (IL-6) in unit, IL-8 in unit, IL-10 in unit, IL-13 in unit, IL-5 in unit, IL-1β in unit, IL-17A in unit, IL-12p70 in unit, tumor necrosis factor-α (TNF-α) in unit, interferon-γ (IFN-γ) in unit, monocyte chemoattratctant protein-1 (MCP-1) in unit, angiotensin II (Ang-II) in unit, superoxide dismutase (SOD) in unit, glutathione (GSH) in unit, nitric oxide levels (NOX) in unit.
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of glucose metabolites in serum
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Serum samples were collected for targetted glucose metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS).
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of neurotransmitter metabolites in serum
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Serum samples were collected for targetted neurotransmitter metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS).
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of microbiomics in nasal mucus
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Nasal mucus samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity).
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of microbiomics in EBC
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
EBC samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity).
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
|
Changes in levels of pituitary-related hormones
Time Frame: Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Including serum levels of cortisol, adreno-cortico-tropic-hormone (ACTH), and thyroid stimulating hormone (TSH).
|
Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00001052-21109
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.